GCRC CAP--ANTENATAL CORTICOSTEROID & THYROTROPIN RELEASING HORMONE

GCRC CAP--产前皮质类固醇

• 批准号: 6278387
• 负责人: LYNNE M BERRY
• 金额: $ 3.92万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6278387
• 关键词: biological transport; body water; clinical research; clinical trial phase I; corticosteroids; endocrine pharmacology; glomerular filtration rate; hormone therapy; human subject; human therapy evaluation; newborn human (0-6 weeks); pregnancy; sodium; thyrotropin releasing hormone

To evaluate the effects of maturational agents on glomerular filtration rate (GFR), free water clearance, sodium clearance, and fractional sodium excretion in infants of treated (prenatal betamethasone or betamethasone plus thyrotropin releasing hormone), and control mothers.

评价促成熟剂对肾小球滤过的影响 GFR、游离水清除率、钠清除率和分数 接受治疗的婴儿的钠排泄（产前检查或 倍他米松加促甲状腺激素释放激素）和对照组母亲。